Chris J. O’Callaghan

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Derek J. Jonker · 4 shared papers, 2016–2026 · strength 0.59
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
2. Ravi Ramjeesingh · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
3. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
4. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
5. Sharlene Gill · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
6. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
7. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
8. Jennifer Jane Knox · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
9. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
10. Daniel John Renouf · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
11. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
12. Yoo‐Joung Ko · 2 shared papers, 2022–2026 · strength 0.33
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
13. Steve Gallinger · 1 shared paper, 2026 · strength 0.21
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
14. Faiyaz Notta · 1 shared paper, 2026 · strength 0.21
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
15. George Zogopoulos · 1 shared paper, 2026 · strength 0.21
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
16. David Goldstein · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
17. Michael M. Vickers · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
18. Wendy R. Parulekar · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
19. Chee Khoon Lee · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
20. Malcolm J. Moore · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.